NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
65 trialsNCT04329728 2026-04-15
OPAL
AVM Biotechnology Inc
Phase 1/2 Recruiting
NCT05006716 2026-04-15
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT05826535 2026-04-15
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT05131022 2026-04-14
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT07195916 2026-04-14
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Phase 1 Recruiting
NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05283720 2026-04-13
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05421663 2026-04-13
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT06395103 2026-04-13
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07260812 2026-04-13
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
TCRx Therapeutics Co.Ltd
Phase 1 Recruiting
NCT05139017 2026-04-07
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07200375 2026-04-03
GlofitReal
Hoffmann-La Roche
Recruiting
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT06890884 2026-04-02
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07284433 2026-04-02
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07059650 2026-04-01
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT06806033 2026-03-31
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT06533579 2026-03-30
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT04830137 2026-03-20
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT04594642 2026-03-18
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1 Recruiting
NCT06500273 2026-03-18
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT07473167 2026-03-16
TC011
TICAROS Co., Ltd.
Phase 1/2 Recruiting
NCT07188558 2026-03-04
PiNACLE-H2H
Lyell Immunopharma, Inc.
Phase 3 Recruiting
NCT06014762 2026-02-27
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Phase 1 Recruiting
NCT06785818 2026-02-23
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis
Recruiting
NCT06830759 2026-02-17
EpcoReal
AbbVie
Recruiting
NCT04775745 2026-02-13
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT05618028 2026-02-12
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
Phase 1 Recruiting
NCT06829771 2026-01-30
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT06043011 2026-01-28
RUBIN
iOMEDICO AG
Recruiting
NCT07368270 2026-01-28
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06667687 2026-01-26
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Recruiting
NCT05512390 2026-01-16
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 1 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT05952024 2025-12-22
ACRUE
AstraZeneca
Phase 2 Recruiting
NCT07189065 2025-12-16
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Recruiting
NCT06929624 2025-11-18
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT04442022 2025-10-03
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3 Recruiting
NCT05780034 2025-10-02
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
Phase 1 Recruiting
NCT02227251 2025-10-01
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT05365659 2025-10-01
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Phase 1 Recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT07124936 2025-08-15
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06375733 2025-08-12
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Recruiting
NCT05660395 2025-07-16
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Phase 1 Recruiting